IL260691A - - Google Patents
Info
- Publication number
- IL260691A IL260691A IL26069118A IL26069118A IL260691A IL 260691 A IL260691 A IL 260691A IL 26069118 A IL26069118 A IL 26069118A IL 26069118 A IL26069118 A IL 26069118A IL 260691 A IL260691 A IL 260691A
- Authority
- IL
- Israel
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281252P | 2016-01-21 | 2016-01-21 | |
| PCT/US2017/013815 WO2017127371A1 (en) | 2016-01-21 | 2017-01-17 | Bruton's tyrosine kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL260691A true IL260691A (https=) | 2018-09-20 |
| IL260691B IL260691B (en) | 2022-07-01 |
Family
ID=59362831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL260691A IL260691B (en) | 2016-01-21 | 2017-01-17 | Burton Tyrosine Kinase Tracers |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10662187B2 (https=) |
| EP (1) | EP3405192B1 (https=) |
| JP (1) | JP6950897B2 (https=) |
| KR (1) | KR102699906B1 (https=) |
| CN (1) | CN109310671B (https=) |
| AU (1) | AU2017208998B2 (https=) |
| CA (1) | CA3009669C (https=) |
| EA (1) | EA201891626A1 (https=) |
| IL (1) | IL260691B (https=) |
| MX (1) | MX384833B (https=) |
| WO (1) | WO2017127371A1 (https=) |
| ZA (1) | ZA201805439B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10793566B2 (en) * | 2016-01-21 | 2020-10-06 | Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. | Bruton's tyrosine kinase inhibitors |
| KR102416971B1 (ko) | 2016-03-11 | 2022-07-04 | 엔젤 파마슈티칼 컴퍼니, 리미티드 | 브루톤형 티로신 키나제를 조절하기 위한 화합물 및 방법 |
| JOP20190113A1 (ar) * | 2016-11-18 | 2019-05-15 | Biocad Joint Stock Co | مثبطات بروتون تيروزين كيناز |
| CN107915584A (zh) * | 2017-12-16 | 2018-04-17 | 江苏长青农化股份有限公司 | 氟磺胺草醚中间体2‑氯‑4‑三氟甲基苯酚的合成方法 |
| CN108276254A (zh) * | 2018-03-26 | 2018-07-13 | 江苏长青农化南通有限公司 | 一种合成2-氯-4-三氟甲基苯酚的方法 |
| CN113365631B (zh) | 2019-01-18 | 2024-08-30 | 杭州邦顺制药有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
| HUE065965T2 (hu) * | 2019-09-26 | 2024-06-28 | Jumbo Drug Bank Co Ltd | 4-fluor-1H-pyrazolo[3,4-C]piridin-származékok mint szelektív bruton-tirozinkináz (BTK) inhibitorok a B-sejtes limfóma és autoimmun betegségek kezelésére |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN113493439B (zh) * | 2020-03-20 | 2022-10-14 | 深圳市塔吉瑞生物医药有限公司 | 取代的丙烯酰胺衍生物及其组合物及用途 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| CN117377675A (zh) * | 2021-06-01 | 2024-01-09 | 正大天晴药业集团股份有限公司 | 含有并环或螺环的布鲁顿酪氨酸激酶降解剂 |
| CN120058798A (zh) * | 2023-11-30 | 2025-05-30 | 武汉人福创新药物研发中心有限公司 | 含双环的tead抑制剂 |
| WO2025202889A1 (en) * | 2024-03-28 | 2025-10-02 | Array Biopharma Inc. | Her2 mutation inhibitors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0615542B2 (ja) * | 1986-07-22 | 1994-03-02 | 吉富製薬株式会社 | ピラゾロピリジン化合物 |
| JP2701281B2 (ja) * | 1988-01-22 | 1998-01-21 | 吉富製薬株式会社 | ピラゾロピリジン化合物 |
| JPH0648941A (ja) * | 1992-06-02 | 1994-02-22 | Yoshitomi Pharmaceut Ind Ltd | 赤血球減少症治療剤 |
| WO1993023036A1 (fr) * | 1992-05-21 | 1993-11-25 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de pyrazole condense optiquement actif, pour le traitement de la thrombocytopenie et de l'erythropenie |
| US6921763B2 (en) * | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| US8729107B2 (en) | 2002-12-06 | 2014-05-20 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
| SE0301906D0 (sv) | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| US8633318B2 (en) * | 2008-09-16 | 2014-01-21 | Proximagen Ltd | Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder |
| EP2464647B1 (en) | 2009-08-11 | 2016-09-21 | Bristol-Myers Squibb Company | Azaindazoles as btk kinase modulators and use thereof |
| US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| EP2487159A1 (en) * | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
| US8377946B1 (en) * | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| JP5985658B2 (ja) * | 2012-01-31 | 2016-09-06 | ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． | ブルトンチロシンキナーゼ阻害薬としての環状分子 |
| WO2014022569A1 (en) * | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Treatment of dry eye |
| WO2014026329A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof |
| WO2014026327A1 (en) * | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
| US8957080B2 (en) * | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| WO2014199171A1 (en) * | 2013-06-12 | 2014-12-18 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
| US9795604B2 (en) * | 2013-10-25 | 2017-10-24 | Pharmacyclics Llc | Methods of treating and preventing graft versus host disease |
| WO2015124570A1 (en) | 2014-02-18 | 2015-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of influenza a virus infection |
| GB201410430D0 (en) * | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
| DK3240785T3 (da) * | 2014-12-29 | 2021-09-27 | Us Health | Småmolekylede hæmmere af laktasedehydrogenase og fremgangsmåder til brug deraf |
| WO2016170545A1 (en) * | 2015-04-22 | 2016-10-27 | Msn Laboratories Private Limited | Process for the preparation of 1-[(3r)-3-[4-amino-3-(4-phenoxyphenvl)-1h- pvrazolo[3,4-d]pyriniidin-1-y1]-1-piperidinvl]-2-propen-1-one and its polymorphs thereof |
-
2017
- 2017-01-17 US US16/070,520 patent/US10662187B2/en active Active
- 2017-01-17 KR KR1020187023916A patent/KR102699906B1/ko active Active
- 2017-01-17 IL IL260691A patent/IL260691B/en unknown
- 2017-01-17 WO PCT/US2017/013815 patent/WO2017127371A1/en not_active Ceased
- 2017-01-17 MX MX2018008815A patent/MX384833B/es unknown
- 2017-01-17 JP JP2018557284A patent/JP6950897B2/ja active Active
- 2017-01-17 CA CA3009669A patent/CA3009669C/en active Active
- 2017-01-17 CN CN201780007631.8A patent/CN109310671B/zh active Active
- 2017-01-17 EA EA201891626A patent/EA201891626A1/ru unknown
- 2017-01-17 AU AU2017208998A patent/AU2017208998B2/en active Active
- 2017-01-17 EP EP17741819.1A patent/EP3405192B1/en active Active
-
2018
- 2018-08-15 ZA ZA201805439A patent/ZA201805439B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102699906B1 (ko) | 2024-08-29 |
| ZA201805439B (en) | 2019-11-27 |
| JP6950897B2 (ja) | 2021-10-13 |
| US20190062328A1 (en) | 2019-02-28 |
| MX384833B (es) | 2025-03-14 |
| AU2017208998A1 (en) | 2018-08-09 |
| AU2017208998B2 (en) | 2021-07-15 |
| KR20180135885A (ko) | 2018-12-21 |
| NZ744554A (en) | 2025-03-28 |
| CN109310671B (zh) | 2021-08-06 |
| WO2017127371A1 (en) | 2017-07-27 |
| JP2019502763A (ja) | 2019-01-31 |
| BR112018014705A2 (pt) | 2018-12-11 |
| EP3405192C0 (en) | 2024-12-11 |
| MX2018008815A (es) | 2019-03-28 |
| CN109310671A (zh) | 2019-02-05 |
| EP3405192A1 (en) | 2018-11-28 |
| EP3405192B1 (en) | 2024-12-11 |
| US10662187B2 (en) | 2020-05-26 |
| CA3009669C (en) | 2023-08-08 |
| CA3009669A1 (en) | 2017-07-27 |
| EA201891626A1 (ru) | 2019-04-30 |
| EP3405192A4 (en) | 2019-07-03 |
| IL260691B (en) | 2022-07-01 |